CIRCULOGENE’s Precision Genomic Profiling Technology Featured in Three AACR 2019 Abstracts
BIRMINGHAM, Ala.--(BUSINESS WIRE)--Mar 25, 2019--CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, will be presenting three abstracts at the 2019 American Association for Cancer Research (AACR) Annual Meeting, March 29 - April 3, 2019, at the Georgia World Congress Center in Atlanta. The poster sessions demonstrate CIRCULOGENE’s rapid, powerful and full-spectrum diagnostics capabilities using proprietary sample preparation coupled with next-generation sequencing (NGS) techniques to assess tumor mutation load at the patient level, even from low-yield, poor quality samples.
The three posters accepted for presentation are:
Abstract No. 437 / 9: “Combining circulating stromal cells with cell free DNA for increased sensitivity in profiling oncogenic mutations and indicates highly aggressive non small cell lung cancer,” investigating the clinical potential of CIRCULOGENE’s Patient Mutation Load (PML) analysis from matched cfDNA, cancer-associated macrophage-like cells (CAMLs), and tumor tissue to evaluate progression free survival (PFS) and overall survival (OS) in non-small-cell lung cancer (NSCLC).
March 31, 2019, 1:00 p.m. - 5:00 p.m. Section 18.
Presenter: Daniel L. Adams, Creatv MicroTech Inc., Monmouth Junction, NJ
Abstract No. 1368 / 7: “Simultaneous cell-free RNA PD-L1 expression and MSI from the same single-tube of blood in solid tumors” investigates the feasibility of simultaneous cfRNA PD-L1 and MSI testing from the same single tube of blood in a liquid biopsy.
April 1, 2019, 8:00 a.m. - 12:00 p.m. Section 19.
Presenter: Glen J. Weiss, M.D., MBA, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Abstract No. 4227 / 17: “Salvage genetic testing on buccal swab samples using liquid in situ amplification identifies genetic mutations from previous test failures” presents findings on the application of liquid in situ amplification (LISA) followed by hereditary testing on previously failed buccal swab samples to yield a genetic testing result.
April 2, 2019, 1:00 p.m. - 5:00 p.m. Section 28.
Presenter: Glen J. Weiss, M.D., MBA, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
CIRCULOGENE is one of very few liquid biopsy laboratories with preliminary data on the clinical application of cfDNA patient mutational load. Built upon its current 50-gene targeted panel and bioinformatics, CIRCULOGENE’s PML analysis showed promising prognostic value in terms of PFS and OS in NSCLC patients. CIRCULOGENE is looking forward to conducting further studies to unlock the full potential of the PML to improve patient care.
“We’re particularly excited about the potential for using cfDNA (in conjunction with CAMLs) for identification of highly aggressive forms of NSCLC with unfavorable prognosis,” said CIRCULOGENE Chief Scientific Officer Chen-Hsiung Yeh, Ph.D. “This research uses our Personalized Gene Profile (CGP) 50-gene panel to determine PML from a single blood sample with increased sensitivity and specificity compared to tumor biopsy. CIRCULOGENE’s unique sample preparation technology was exclusively selected for this study. Given the rarity of CAMLs in the blood, the starting material usually has just a few to several hundred purified CAMLs.”
All poster sessions take place in Exhibit Hall B. The full text of Regular Abstracts accepted for presentation are posted on the AACR Online Itinerary Planner.
The highly accurate, automated and scalable cell-free DNA and RNA technology platform from CIRCULOGENE enables comprehensive genomic testing services. These capabilities help oncologists and pathologists select the right clinical trials and the most effective cancer therapies available for their patients, as well as monitoring patient responses, drug resistance, minimal residual disease and relapse.
CIRCULOGENE is the only company that provides circulating DNA, RNA (somatic and germline), and MSI cancer immunotherapy testing from a single tube of blood. Industry-leading turnaround times ensure that complete testing results are available to physicians and their patients within one week, all from a single 4 mL tube of blood, no matter which test or how many tests are ordered.
CIRCULOGENE is a Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited laboratory and is registered as a verified U.S. federal contractor. For more information, visit our website, connect with us on LinkedIn, Facebook and Twitter, email us at firstname.lastname@example.org or call 855-614-7083. Clinicians interested in ordering tests may visit the Contact page on CIRCULOGENE’s website.
Headquartered in Birmingham, Ala., CIRCULOGENE is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed a next-generation sequencing (NGS) method to provide full genomic load analysis from one standard tube of blood in one week, enabling more accurate data to help clinicians and their patients choose targeted therapies, monitor efficacy and monitor for recurrence. One Tube, One Week, Complete Results. Somatic + Germline; Blood + Tissue + Buccal; DNA + RNA + Immunotherapy. For more information, visit www.circulogene.com or call 855-614-7083.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190325005069/en/
CONTACT: Media Contact
MedTech Content Marketing
KEYWORD: UNITED STATES NORTH AMERICA ALABAMA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS HOSPITALS INFECTIOUS DISEASES ONCOLOGY PHARMACEUTICAL OTHER HEALTH RESEARCH FDA SCIENCE MANAGED CARE
Copyright Business Wire 2019.
PUB: 03/25/2019 10:10 AM/DISC: 03/25/2019 10:10 AM